Jason M. Aryeh serves as a member of the Board of Directors of Aralez Pharmaceuticals Inc. since February 5, 2016. Mr. Aryeh is the Founder and Managing General Partner of JALAA Equities, LP, a private hedge fund focused on the life-sciences sector, and has served in such capacity since 1997. Mr. Aryeh serves as the Chairman of the Board of Directors of Novelion Therapeutics (NASDQ: NVLN) and serves on its Corporate Nominating & Governance Committee. Mr. Aryeh serves on Ligand Pharmaceuticals (NASDQ: LGND) Board of Directors and serves as the Chairman of its Corporate Nominating & Governance Committee and as a member of its Compensation Committee. Mr. Aryeh serves as Lead Independent Director on the Board of CorMatrix Cardiovascular, a regenerative medical device company. Mr. Aryeh also serves as a Directors of the Cystic Fibrosis Foundation’s Therapeutic Board.
Mr. Aryeh earned a B.A. in economics, with honors, from Colgate University, and is a member of the Omnicron Delta Epsilon Honor Society in economics.